ZyVersa Therapeutics (ZVSA) Stock Overview
Operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ZVSA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ZyVersa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$1.94 |
| 52 Week Low | US$0.11 |
| Beta | 0.80 |
| 1 Month Change | 42.39% |
| 3 Month Change | 30.45% |
| 1 Year Change | -86.54% |
| 3 Year Change | -99.90% |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZVSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | 3.6% | -0.4% |
| 1Y | -86.5% | 26.9% | 12.7% |
Return vs Industry: ZVSA underperformed the US Biotechs industry which returned 26.9% over the past year.
Return vs Market: ZVSA underperformed the US Market which returned 12.7% over the past year.
Price Volatility
| ZVSA volatility | |
|---|---|
| ZVSA Average Weekly Movement | 22.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZVSA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZVSA's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 7 | Steve/Steven Glover | www.zyversa.com |
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC.
ZyVersa Therapeutics, Inc. Fundamentals Summary
| ZVSA fundamental statistics | |
|---|---|
| Market cap | US$1.54m |
| Earnings (TTM) | -US$25.70m |
| Revenue (TTM) | n/a |
Is ZVSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZVSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$25.70m |
| Earnings | -US$25.70m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZVSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 20:25 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ZyVersa Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | NOBLE Capital Markets, Inc. |